News Releases

SEATTLE --(BUSINESS WIRE)--Sep. 15, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase

SEATTLE --(BUSINESS WIRE)--Sep. 7, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of its management team will present at the

- Conference call and webcast today at 4:30 p.m. ET - SEATTLE --(BUSINESS WIRE)--Aug. 10, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a

SEATTLE --(BUSINESS WIRE)--Aug. 4, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial

- First Patient Dosed in NEON-2 Clinical Trial - SEATTLE --(BUSINESS WIRE)--Jun. 30, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today a

SEATTLE --(BUSINESS WIRE)--Jun. 24, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today that the first patient has been dosed in Synergy, a

SEATTLE --(BUSINESS WIRE)--Jun. 8, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today Alpine is set to join the broad-market Russell 3000®

Alpine to hold an ALPN-202 Investor Event on Friday, June 4 at 7:00pm EDT SEATTLE --(BUSINESS WIRE)--Jun. 4, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases,

SEATTLE --(BUSINESS WIRE)--Jun. 2, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today made an oral presentation of preclinical data from the company’s

SEATTLE --(BUSINESS WIRE)--Jun. 2, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the appointment of industry veteran Zelanna Goldberg,